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Abstract 
Despite an increasing body of knowledge on the adverse clinical sequelae associated with late 
preterm birth and early term birth, relatively little is known about their economic 
consequences or the cost-effectiveness of interventions aimed at their prevention or 
alleviation of their effects. This paper provides an overview of the health economic evidence 
surrounding late preterm and early term birth. The paper covers evidence surrounding 
hospital resource use associated with late preterm and early term birth, economic costs 
associated with late preterm and early term birth, and economic evaluations of prevention and 
treatment strategies. The paper highlights the limited perspective and time horizon of most 
studies of economic costs in this area. It also highlights the limited evidence surrounding 
health economic aspects of early term birth. The paper highlighting gaps in current 
knowledge and discusses directions for future research in this area, including the need for 
validated tools for measuring preference-based health-related quality of life outcomes in 
infants that will aid cost-effectiveness based decision making. 
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Introduction 
 
Preterm births, namely births before 37 completed weeks’ gestation, or fewer than 259 days 
since the first day of the mother’s last menstrual period [1], have traditionally been 
subdivided into a number of subcategories based on gestational age, ranging from extremely 
preterm birth (<28 weeks’ gestation) to late preterm birth (34+0-36+6 weeks’ gestation) [2]. 
More recently, births at term have been subdivided into early term births, which occur 
between 37+0 and 38+6 weeks’ gestation, and births occurring at full term (39+0-41+6 weeks’ 
gestation) [3]. A recent population-based retrospective analysis of singleton live 
births conducted in six high income countries revealed that late preterm birth rates during 
2006-2014 were 4.8% in Canada, 3.6% in Denmark, 3.3% in Finland, 3.8% in Norway, 3.6% 
in Sweden, and 6.0% in the United States, whilst early term birth rates were 25.3% in 
Canada, 18.8% in Denmark, 16.8% in Finland, 17.2% in Norway, 18.7% in Sweden, and 
26.9% in the United States [4]. The study provided evidence that late preterm and early term 
birth rates decreased in the United States over the study period, and an association was 
observed between early term birth rates and decreasing clinician-initiated obstetric 
interventions [4]. Of particular concern to clinicians, however, is the increased risk of adverse 
clinical sequelae during the neonatal period and later childhood associated with late preterm 
birth and early term birth. Epidemiological evidence suggests that infants born late preterm 
are at increased risk of acute respiratory disorders immediately after birth [5], delayed 
feeding development [6], early childhood mortality [7], neurodevelopmental disability at two 
years of age [8], and cognitive deficits [9], learning difficulties [10] and behaviour problems 
[9] at school age, when compared to full term infants. Infants born early term are also at 
increased risk of a host of adverse outcomes, including neonatal admissions [11], prolonged 
hospitalisations [12], health complications during early childhood [13, 14], and 
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developmental delay [15], when compared to full term infants. Although the adverse clinical 
sequelae during childhood associated with late preterm birth and early term birth are likely to 
affect several areas of the economy, little is known about their economic consequences or the 
cost-effectiveness of interventions aimed at their prevention or alleviation of their effects. 
Previous review articles of economic evidence have focussed on preterm birth in its entirety 
without recourse to the evidence surrounding early term birth, and focussed on economic 
costs rather than broad health economic aspects [16, 17]. This paper examines the health 
economic aspects of late preterm birth and early term birth, beginning with an overview of 
methods, and moving on to discussion of key evidence. It does not systematically review all 
evidence in the field, but rather highlights key evidence likely to be of interest to the clinical 
and academic communities. 
 
An overview of health economic methods  
 
Cost-of-illness studies or studies of economic burden estimate the economic costs of a 
particular disease or condition or health state [18]. Applications can differ in terms of the 
categories of costs that they cover, which will depend on the study perspective. The 
perspective of an economic analysis typically falls into one of three categories, namely the 
healthcare system, public sector or societal. The study perspective should be informed by 
national methodological guidance; in England, for example, the National Institute for Health 
and Care Excellence (NICE) recommends including National Health Services (NHS) and 
personal social services as a minimum [19]. Applications to late preterm birth and early term 
birth may need to consider economic costs borne by several sectors of the economy, as well 
as for individuals. The sick infant may require support from social service departments, for 
example, upon their discharge from hospital. The parents of sick infants may have to forego 
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other productive activities (paid or unpaid work) in order to spend time with them; their 
transport costs to and from the neonatal unit may be considerable, and care for other children 
may have to be arranged. In contexts such as this, there is considerable value in also adopting 
a broader societal perspective, at least as part of a sensitivity analysis.  
     The total economic costs for a participant or individual within a cost-of-illness study or 
study of economic burden can be expressed as a compound formula: 
Ci = ∑ Qij.UCj 
where Ci represents the total cost for individual i, Qij represents the quantity of resource item 
j by individual i, and UCj represents the unit cost of resource item j. This requires the 
estimation of unit costs for each element of resource use consumed by the individual over the 
time horizon of interest. Quantities of resource can be estimated within the case report forms 
of randomised controlled trials, through extraction from routine health service information 
sources, or from primary surveys, reviews of published studies, or from expert opinion 
(Delphi panels). It is relatively unusual that a complete profile of resource use can be 
obtained from a single source. 
     Theoretically, unit costs attached to resource inputs should be based on the economic 
notion of opportunity cost, which represents the value of the resource in its most highly 
valued alternative use [19]. In the absence of competitive health markets, however, nationally 
representative health care tariffs, such as NHS Reference Costs, in England, for clinically 
similar treatments [20], and the compendia of unit costs covering hospital and community 
health and social care services [21], in England, are assumed to approximate to opportunity 
costs. In jurisdictions with systems of billing and fee-for-service payment of providers, 
market prices are deflated using cost-to-charge ratios to more accurately reflect opportunity 
costs [22]. There may be circumstances where unit cost estimates for health resources are not 
readily available and have to be generated from first principles using alternative approaches, 
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including time and motion studies, diary methods, work sampling, interviews with key 
caregivers, case note analysis and  analyses of patient activity databases. The estimation of 
total economic costs requires unit cost estimates from previous years to be adjusted using a 
health care specific price index to reflect a more recent price level. In addition, any costs 
accruing beyond the first year of follow-up are normally discounted or reduced to present 
values to take account of differences in potential productivity of resources over time. A final 
analytic requirement is the need for sensitivity analysis to account for uncertainty 
surrounding elements of the cost estimation process or calculus. 
     Many health economists argue that cost-of-illness studies or studies of economic burden 
tell us about the scale, in economic terms, of a particular health problem [18]. However, they 
tell us little about prioritising finite resources as they do not evaluate interventions to address 
health or related needs or well-being associated with the disease or condition or health state 
of interest [18]. In contrast, health economic evaluation compares alternative interventions or 
programmes in terms of their costs and consequences. A common vehicle for the conduct of 
health economic evaluation is the randomised controlled trial where individual level costs and 
consequences are collected for the trial population [23]. However, trial-based economic 
evaluations have a number of limitations including potentially truncated time horizons, 
limited comparators, restricted generalisability to different settings or countries, and the 
failure to incorporate all relevant evidence [23]. As a result, decision analytic modelling, 
which involves application of mathematical techniques that synthesize data from multiple 
sources, including randomised controlled trials or studies with other designs, provides an 
alternative vehicle for the conduct of health economic evaluation [24]. 
     There are four broad approaches to health economic evaluation, namely cost-minimization 
analysis (CMA), cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-
benefit analysis (CBA). These alternative forms broadly adopt the same approach to cost 
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measurement and valuation, but differ in how consequences are measured and valued. CMA 
assumes that the competing interventions under consideration are equal with respect to 
consequences and that the study design allows the equivalence of consequences to be tested 
[25]. By implication, only costs are important in CMA and the least costly strategy is 
preferred. A CEA measures the consequences of competing interventions in natural or 
physical units. The outputs of a CEA are normally summarised in terms of an incremental 
cost effectiveness ratio (ICER), which represents the difference in costs between two 
interventions divided by the difference in effects. A CEA can only be used to compare 
interventions that produce the same kinds of consequences. It cannot be used to compare 
interventions whose consequences are measured in different units; for example, it cannot 
compare the treatment of late preterm infants, expressed in terms of acute respiratory disorder 
avoided, with clinically defined consequences of schizophrenia treatment or cancer treatment. 
To make these broader comparisons, a common “currency” for measuring consequences is 
needed. This can be achieved in two different ways, one leading to CUA and the other to 
CBA. In CUA, a common currency is achieved by valuing consequences using preference-
based measures of health, such as quality-adjusted life years (QALYs), which attempt to 
capture health gains in a single metric combining life-years gained and health-related life-
quality enhanced [26]. In CBA, the consequences of health interventions are measured and 
valued in monetary terms. 
     In an economic evaluation, a new intervention may turn out to be more effective but also 
more costly than usual practice, or conceivably may be less effective but also less costly than 
usual practice. A trade-off then exists between effect and cost. In CBA, this is dealt with by 
subtracting the incremental cost (relative to the comparator) from the incremental benefit on a 
linear scale where both are valued in the same monetary metric. Within CEA and CUA, 
however, the maximum willingness to pay for the unit of effect (the natural or physical unit 
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in the case of CEA and the QALY in the case of CUA) is required to determine whether the 
intervention is cost-effective. In England and Wales, for example, a maximum acceptable 
ICER of £20,000 to £30,000 per QALY gained is recommended for regulatory and 
reimbursement decisions [19]. 
     The paper now turns to the health economic evidence surrounding late preterm and early 
term birth. 
 
Hospital resource use associated with late preterm and early term birth 
 
Hospital resource use represents a major driver of additional economic costs associated with 
late preterm and early term birth. This is initially felt during the neonatal period. A 
retrospective cohort study of 38,807 singleton live births with no major congenital anomalies, 
delivered at 34–41 weeks of gestation to Canadian mothers in 2002–11, revealed that infants 
born late preterm and early term were at increased risk of neonatal intensive care unit 
admission [late preterm adjusted relative risk (aRR) = 6.14, 95% confidence interval (CI) 
5.63, 6.71; early term aRR = 1.54, 95% CI 1.41, 1.68] compared to infants born at term [27]. 
This pattern varies across health systems and jurisdictions with differing clinical protocols 
[28].  
     Several studies have shown that infants born late preterm and early term are also at 
increased odds of hospital admission beyond the neonatal period and through early childhood 
[13, 29-32]. For example, a retrospective database analysis covering 599,753 liveborn infants 
born in New South Wales, Australia, between 2001 and 2007 and linked to hospital discharge 
records revealed that infants born late preterm and early term were are at increased adjusted 
odds of one hospital readmission (adjusted odds ratio (aOR): 1.52 and 1.20, respectively) and 
more than one hospital readmission (aOR: 1.87 and 1.36, respectively) during the first year of 
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life, in comparison with infants born at full term [31]. A separate nation-wide population-
based study of 696,698 liveborn infants that used a French medico-administrative database 
revealed that infants born at 34 weeks gestation and at 37 weeks gestation were at increased 
relative risk (2.2 (95% CI: 2.1, 2.4) and 1.3 (95% CI: 1.3, 1.3), respectively) of post-neonatal 
hospital admission during the first year of life, in comparison with infants born at full term 
[32]. Limited evidence suggests that the re-hospitalization risk remains elevated through later 
stages of childhood. A retrospective cohort study of all live singleton births in Western 
Australia dating back to 1980 and without congenital anomalies revealed incidence rate ratios 
for hospital admission of 1.33 (95%CI: 1.30, 1.36) and 1.13 (95%CI: 1.11, 1.14) between the 
5th and 12th years of life and 1.14 (95%CI: 1.11, 1.18) and 1.08 (95%CI: 1.06, 1.10) between 
the 12th and 18th years of life for children born late preterm and early term, respectively, in 
comparison with children born at full term [33]. Common drivers for hospitalization in 
children born late preterm and early term included infection, injury, and respiratory related 
causes between the 5th and 12th years of life, and injury, oral cavity-related and infection 
between the 12th and 18th years of life [34]. Of further note is that some population based 
cohorts have revealed that infants born late preterm and early term are at also increased risk 
of hospital emergency department visit through childhood [35], which should be considered 
as an additional driver of economic costs. 
 
Economic costs associated with late preterm and early term birth 
  
Table 1 provides an overview of 17 key studies published since 2000 that have estimated the 
economic costs associated with late preterm and early term birth [3, 36-51]. The table 
summarises the methods of each study, including the date of birth of the study population, 
location, type of study, sample size, comparator groups in terms of gestational ages at birth, 
10 
 
categories of economic costs considered, the currency and price date in which costs were 
estimated, and study time horizon. The table also summarizes the economic costs estimated 
by each study for relevant comparator groups. Where individual studies also estimated 
economic costs for infants born at earlier gestations (<34 weeks), the results for those 
gestational groups are not presented. 
     Seven studies reported economic costs associated with late preterm birth during the 
infant’s initial hospitalization with the study perspective limited to the health sector [39, 41, 
42, 47, 49-51]. A consistent inverse association was observed between gestational age at birth 
and initial hospitalization costs regardless of date of publication, country of publication, 
underpinning study design, costing methodology or the denominators applied within the cost 
calculus (live births or survivors). Two studies estimated a less than two-fold differential in 
initial hospitalization costs between infants born late term and a comparator group born at 
term (≥37 weeks) [39, 49], whilst a further two studies estimated an 8-10 fold differential in 
initial hospitalization costs between infants born at 34 weeks gestation and those born at term 
[42, 50]. A further study analysed state-level linked vital statistics and hospital discharge 
records in California covering 84,540 infants born late preterm and 92,241 infants born at 
term [47]. The authors found that an intervention strategy that is effective at delaying 
delivery at 34 weeks gestation by one week (two weeks) would result in mean economic 
savings (in terms of neonatal costs prevented) of $4,528 ($7,090) (US$, 2003 prices). 
     Ten studies reported health service costs associated with late preterm birth beyond the 
period of the infant’s initial hospitalization [3, 36-38, 40, 43-46, 48]. As with interpretation of 
studies that focused on the costs associated with the initial hospitalisation, comparability of 
results across studies is complicated by a number of differences in study design. Notably, the 
period of follow-up varied between the first year of life [37, 44, 48] and the first eighteen 
years of life [43]. All studies generated an inverse relationship between gestational age at 
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birth and long-term health service costs, regardless of period of follow-up. Petrou and 
colleagues conducted analyses based on data extracted from the Oxford Record Linkage 
Study (ORLS), a large collection of linked, anonymised birth registrations, death certificates 
and statistical abstracts of NHS hospital inpatient and day-case admissions within 
Oxfordshire and West Berkshire in England. An initial analysis revealed a 3.3-fold 
differential in hospital service costs between infants born at 32-36 weeks gestation (without 
disaggregation into more granular categories) and those born at term, during the first five 
years of life [45]. A subsequent analysis that extended the period of follow-up to cover the 
first ten years of life revealed a 4.5-fold differential in hospital service costs between the 
same comparator groups, suggesting that the economic effects of impairment associated with 
moderate and late preterm birth do not dissipate during mid-childhood. Authors from the 
same research group subsequently developed a decision-analytic model that generated 
estimates of economic costs associated with late preterm birth, drawing upon evidence from 
the ORLS, as well as from other cohort studies [43]. The model estimated a mean 
incremental health and social care cost associated with late preterm birth of £10,498 (£ 
sterling, 2006 prices) during the childhood years. The model also revealed that mean 
education costs, parental expenses and the value of lost productivity as a result of the child’s 
health state were all higher following late preterm birth than birth at term. 
     The studies by Lo et al. [42] and Helle et al. [3] provide granulated assessments of 
economic costs within gestational age categories of term-born infants, the former limited to 
the period of the initial hospitalization whilst the latter covered the first three years of life. 
The study by Lo et al. [42] was based on a retrospective chart analysis of 240,179 singleton 
deliveries in the United States and provided no indication of a significant difference in initial 
hospitalization costs for infants born early term compared to those born at full term. In 
contrast, the prospective cohort study by Helle et al. [3], conducted in Finland, showed that 
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children born early term had greater morbidity and health care costs in each year of the first 
three years of life compared with infants born at full term, with cost differences primarily 
driven by airway diseases and opthalmological and motor problems. 
 
Cost-effectiveness of prevention strategies 
 
The attendant problems and adverse clinical and economic sequelae of late preterm and early 
term birth have heightened interest in prevention strategies and their cost-effectiveness [52]. 
Strategies that involve identifying women at high risk of delivering early are constrained by 
low positive predictive values of existing prediction tests for symptomatic women with 
threatened preterm birth or for asymptomatic high risk women [52]. Tsoupras and colleagues 
conducted a decision-analytic modelling based economic evaluation to estimate the potential 
cost-effectiveness of alternative ‘test-and-treat’ strategies in the prevention of spontaneous 
preterm birth before 34 and 37 weeks’ gestation [53]. The model drew upon evidence from 
systematic reviews of clinical effectiveness and predictive accuracy studies. Prophylactic fish 
oil in asymptomatic women, without prior testing, was highlighted as potentially cost-
effective in preventing threatened preterm labor before 34 weeks’ gestation. Furthermore, in 
symptomatic women with a viable pregnancy, indomethacin without prior testing was 
identified as a potentially cost-effective strategy to prevent preterm birth occurring before 37 
weeks’ gestation. 
         Einerson and colleagues used a decision-analytic model to estimate the cost-
effectiveness of risk-based screening compared to universal cervical length screening or no 
screening for preterm birth prevention in low-risk women [54]. The authors found that, in 
comparison to the risk-based strategy, universal screening was associated with an ICER of 
$21,144 per QALY gained (US$, 2014 prices). However, the authors’ analysis was 
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constrained by a paucity of validated tools for measuring infants’ preference-based health-
related life-quality outcomes for the purposes of QALY calculation. 
     Increasing interest in progesterone as a potential preventive intervention for preterm birth 
led Pizzi and colleagues to conduct an economic evaluation of vaginal progesterone gel [55]. 
Using a decision-analytic model informed by patient-level data from the PREGNANT trial, 
and which grouped women into gestational age categories, the authors estimated that vaginal 
progesterone was associated with cost savings and health benefits, expressed in terms of 
preterm birth averted. The authors’ analysis would benefit from data included in a more 
recent meta-analysis of vaginal progesterone for preventing preterm birth [56]. 
     Other analysts have examined the cost-effectiveness of prevention strategies implemented 
after 34 week’s gestation in pregnancies complicated by specific disorders, such as 
gastroschisis [57] or non-severe hypertensive disorders [58]. These analyses inform the most 
cost-effective timing of delivery under differing clinical scenarios by balancing relative 
economic costs against the risk of stillbirth, neonatal death or maternal complications. 
      
Cost-effectiveness of treatment strategies 
A number of pharmacological and surgical interventions, forms of developmental care, 
organisational approaches and other intervention strategies targeted at infants born late 
preterm or early term have been evaluated using randomised controlled trials and quasi-
experimental designs. This accumulation of evidence on clinical effectiveness has been 
accompanied by a limited number of economic evaluations of treatment options. Petrou and 
colleagues conducted a trial-based economic evaluation of neonatal extracorporeal membrane 
oxygenation (ECMO), compared to conventional management, in mature (gestational age at 
birth >or= 35 weeks, birth weight >or= 2000 g) newborn infants with severe respiratory 
failure (oxygenation index >or= 40) [59]. Data were collected about all major health service 
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resource inputs through trial case report forms, routine data sources and parental interviews. 
Deaths were captured by the trial monitoring procedures, whilst standardized 
neurodevelopmental assessments were performed in the homes of surviving infants by a 
single paediatrician. Over four years of follow-up, the incremental cost of neonatal ECMO 
was £16,707 (95% CI: £9828 to £37,924) per life year gained and £24,775 (95% CI: £13,106 
to £69,690) per disability-free life year gained (£ sterling, 2001 prices). Notably, the authors 
highlight the lack of validated tools for QALY measurement in this age group, thereby 
limiting the potential for cost-effectiveness comparisons with interventions in other areas of 
health care. A subsequent economic evaluation conducted by the authors that was based on 
seven year follow-up data within the same trial estimated the incremental cost per disability-
free life year gained associated with neonatal ECMO at £23,566 (£ sterling, 2002-3 prices). 
Xie and colleagues using a decision-analytic model to estimate the incremental cost-
effectiveness of a system-based approach for the management of neonatal jaundice and the 
prevention of kernicterus in late-preterm and term (≥35 weeks) infants, compared with the 
traditional practice based on visual inspection and selected bilirubin testing [60]. The 
incremental cost-effectiveness of the system-based approach was estimated at $26,279 per 
life year gained and $65,698 per QALY gained (Can$, 2008 prices), but the QALY-based 
analysis was again constrained by a lack of validated tools for measuring infants’ preference-
based health-related life-quality outcomes. 
     A number of economic evaluations have estimated the cost-effectiveness of palivizumab 
as a prophylaxis against respiratory syncytial virus infection in moderate and late preterm 
infants with [61, 62] and without [63, 64] additional risk factors. All the evaluations 
concluded that palivizumab is a cost-effective prophylactic despite variations in the 
jurisdictions in which the evaluations were conducted and concomitant variations in health 
care practices. 
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Discussion 
 
Infants born late preterm are at increased risk of acute respiratory disorders immediately after 
birth [5], delayed feeding development [6], early childhood mortality [7], 
neurodevelopmental disability at two years of age [8], and cognitive deficits [9], learning 
difficulties [10] and behaviour problems [9] at school age, when compared to full term 
infants. Infants born early term are also at increased risk of a host of adverse outcomes, 
including neonatal admissions [11], prolonged hospitalisations [12], health complications 
during early childhood [13, 14], and developmental delay [15], when compared to full term 
infants. Given the adverse clinical sequelae associated with late preterm and early term birth, 
it is imperative to understand their potential economic consequences. This paper provides an 
overview of the health economic evidence on late preterm birth and early term birth. 
Although the published data are sparse, they consistently show that the inverse association 
between gestational age at birth and economic costs observed at earlier gestations [16, 65] 
extends to later gestational ages at birth, regardless of study date, jurisdiction, underpinning 
study design, costing methodology, the denominators applied within the cost calculus or 
period of follow-up. It is noteworthy that existing economic research in this area is hampered 
by a paucity of epidemiological studies that accurately quantifies neonatal morbidity and 
longer term adverse outcomes, in particular for infants born early term, or that identify risk 
factors contributing to these outcomes. There is therefore a clear need for prospective, 
comprehensive data collection for infants born between 34 and 38 weeks’ gestation to allow 
quantification of economic outcomes for this group. This is essential, first, to highlight areas 
in which changes in perinatal care may improve outcomes and, second, to inform efficient 
allocation of finite health care resources for children born at these gestational ages and their 
families. 
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     Only three studies, to the knowledge of the authors, have attempted to quantify the non-
health service costs associated with late preterm birth [38, 40, 43], whilst no attempt has been 
made to quantify the non-health service costs associated with early term birth. Where 
disaggregated cost values are presented, they suggest that non-health service costs borne by 
infants born late preterm exceed those born by term-born infants. The potential to inform 
budgetary and service planning extends therefore to non-health service providers, such as 
social and education service providers. Moreover, there are several other categories of 
economic costs that could usefully be considered in future economic analyses. These include 
costs borne by local authorities and voluntary organisations, such as adaptations that have to 
be made to the child’s home as a result of their impaired state of health, and additional costs 
borne by families and informal carers as a result of adjustments to their lifestyles and 
working patterns. Methods for estimating these broader economic costs include incorporating 
economic questionnaires and diaries into prospective cohort studies, although the value of 
these data should be balanced against the potential burden imposed on families. 
     Turning to economic evaluation, there are several prevention and treatment strategies 
surrounding late preterm and early term birth for which cost-effectiveness evidence is 
lacking, for example, cooling for newborns with hypoxic ischaemic encephalopathy [66], 
surfactant for meconium aspiration syndrome [67], and pulse oximetry screening for critical 
congenital heart defects [68]. Future randomised controlled trials of intervention strategies 
targeting late preterm and early infants, with and without additional risk factors, should 
ideally incorporate prospective economic evaluations, and measure and value both costs and 
health consequences over extended periods of follow-up. Such evidence is required to inform 
the efficient allocation of scarce resources. However, there will clearly be circumstances 
where randomised controlled trials will not be feasible and assessments of cost-effectiveness 
will have to be based on evidence from decision-analytic models. A particular 
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methodological challenge faced by these economic evaluations is the lack of validated tools 
for measuring preference-based health-related quality of life outcomes in infants. 
Development of such tool will be needed to aid cost-effectiveness based decision-making 
using the incremental cost per QALY gained metric. 
     In conclusion, this paper provides an overview of health economic aspects of late preterm 
birth and early term birth. Future research should focus particularly on the economic costs 
associated with early term birth and the cost-effectiveness of strategies aimed at its 
prevention or amelioration of its effects. 
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Table 1: Studies published since 2000 reporting economic costs associated with late preterm birth and early term birth 
Study Date of 
birth of 
study 
population 
Location Type of study Sample size Gestational 
age(s) (weeks) 
Type of 
economic costs 
Currency, 
price date 
Time 
horizon 
Results± 
Berard et al 
[36]  
1997-2000  Canada 
(Quebec) 
Retrospective 
cohort study 
33-36 weeks: 
2176 
≥37 weeks: 
33,879 
 
33-36  
≥37 
Hospitalisation, 
physician visits, 
emergency 
department visits 
and prescriptions 
following initial 
hospitalisation 
Can$, 2003  First three 
years of life 
33-36 weeks: 
Re-hospitalisations: 1727  
Physician visits: 977  
Emergency department visits: 2  
Prescriptions: 388  
≥37 weeks: 
Re-hospitalisations: 628  
Physician visits: 766  
Emergency department visits: 1  
Prescriptions: 257  
Bird et al [37] 2001-2005 USA 
(Arkansas) 
Retrospective 
analysis of 
Medicaid 
claims 
database 
34-36 weeks: 
5188  
37-42 weeks: 
15,303 
34-36   
37-42  
Hospital inpatient 
and outpatient 
care 
US$, price 
date not 
specified 
First year of 
life 
Inpatient cost per survivor: 
34-36: 3027 
37-42: 2183 
Outpatient cost per survivor: 
34-36: 1560 
37-42: 1316 
Total health care cost per 
survivor: 
34-36: 4541 
37-42: 3472 
Clements et al 
[38] 
1999-2000 USA 
(Massachuse
tts) 
Retrospective 
analysis of 
claims 
database 
34-36 weeks: 
5682  
≥37 weeks: 
69,274 
34-36   
≥37 
Health and social 
services 
US$, 2003 Initial 
discharge to 
three years 
Mean cost per survivor: 
34-36: 1372 
≥37: 725 
Gilbert et al 
[39] 
1996 USA 
(California) 
Retrospective 
analysis of 
state-level 
linked vital 
statistics and 
discharge 
records 
34-36 weeks: 
32,295 
≥37 weeks: 
106,087 
 
34-36  
≥37 
Hospital US$, price 
date not 
specified 
Initial 
hospital-
ization 
Mean cost per survivor: 
34-36 weeks: 7,232 
≥37 weeks: 3,860 
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Helle et al [3]  2006-2008 Finland 
(Municipaliti
es of 
Helsinki, 
Espoo, 
Vantaa) 
Prospective 
cohort study 
34-36 weeks: 
1164  
37-38 weeks: 
4586   
39-41 weeks: 
21,812  
>41 weeks: 
2005 
34-36  
37-38 
39-41 
>41  
Specialized care, 
primary care, 
private health care, 
medications 
€, 2011  First three 
years of life 
Median cost per survivor: 
34-36 weeks: 5621 
37-38 weeks: 2987 
39-41 weeks: 2700 
>41 weeks: 2679 
Khan et al 
[40]  
2009-10 UK  
(East 
Midlands) 
Prospective 
cohort study 
34-36 weeks: 984 
≥37 weeks: 1258 
34-36 
≥37  
Postnatal, neonatal, 
transfers, post-
mortems, surgery, 
investigations, 
community care, 
special equipment, 
adaptations, lost 
earnings 
£, 2010-11 First two 
years of life 
34-36 weeks: 
Neonatal care: 2827.01; Other 
hospital care: 1642.21; 
Community care: 1059.32; 
Medications: 7.15; Lost 
earnings: 255.95; Special 
equipment: 4.87; Adaptations: 
26.97; Total health services: 
5535.70; Total societal: 5823.49 
≥37 weeks: 
Neonatal care: 172.66; Other 
hospital care; 673.76, 
Community care: 1005.24; 
Medications: 7.99; Lost 
earnings: 155.86 Special 
equipment: 3.32; Adaptations: 
36.70; Total health services: 
1859.65; Total societal: 2055.52 
Lim et al [41]  2005-2006 Canada Retrospective 
national 
register study 
Singletons:  
34-36 weeks: 
9716  
≥37 weeks: 
189,750 
Multiples:  
34-36 weeks: 
2370  
≥37 weeks: 2742 
34-36 
≥37  
Hospital Can$, price 
date not 
specified 
Initial 
hospital-
ization 
34-36 weeks:  
5047 (singletons) 
6494 (multiples) 
≥37 weeks:  
1050 (singletons)  
1871 (multiples) 
 
Lo et al [42]  2000-2008 USA Retrospective 
chart analysis 
Singleton 
deliveries: 
240,179  
24-42  Hospital US$, price 
date not 
specified 
Initial 
hospital-
ization 
34 weeks: 9740 
35 weeks: 5015 
36 weeks: 2413 
28 
 
37 weeks: 1469 
38 weeks: 1070 
39 weeks: 994 
40 weeks: 1017 
41 weeks: 1058 
42 weeks: 1072   
Mangham et 
al [43]  
2006 England and 
Wales 
Decision-
analytic model 
populated with 
data from 
administrative 
population-
based 
databases 
34-36 weeks: 
32,812 
≥37 weeks: 
621,618 
34-36 
≥37 
Hospital inpatient, 
hospital 
outpatient, 
community health 
and social care, 
education services 
£, 2006 First 18 
years of life 
34 weeks: 60,437 
35 weeks: 52,086 
36 weeks: 49.029 
≥37 weeks: 41,813 
 
McLaurin et 
al [44]  
2004 USA Retrospective 
analysis of 
insurance 
database 
33-36 weeks: 
1683  
≥37 weeks: 
33,745 
33–36 
≥37 
Inpatient 
hospitalisations, 
well-infant 
physician office 
visits, outpatient 
hospital services, 
home 
health/private 
nurse, acute care 
physician office 
visits, prescription 
drugs, other 
professional 
US$, price 
date not 
specified 
First year of 
life 
Initial hospitalization: 
33-36 weeks: 26,054 
≥37 weeks: 2087 
Following initial discharge: 
33-36 weeks: 12,247 
≥37 weeks: 4069 
Petrou et al 
[45] 
1970-1993 UK 
(Oxfordshire 
and West 
Berkshire) 
Retrospective 
analysis of 
linked vital 
statistics 
and NHS 
records 
financial returns 
32-36 weeks: 
11,728 
≥37 weeks: 
226,120 
32–36 
≥37 
Hospital inpatient 
services 
£, 1998-99 First five 
years of life 
32–36 weeks: 4378 
≥37 weeks: 1333 
Petrou et al 
[46] 
1978-1988 UK 
(Oxfordshire 
and West 
Berkshire) 
Retrospective 
analysis of 
linked vital 
statistics 
and NHS 
records 
financial returns 
32-36 weeks: 
4485 
≥37 weeks: 
90,236 
32–36 
≥37 
Hospital inpatient 
services 
£, 1998-99 First five 
years of life 
32–36 weeks: 7394 
≥37 weeks: 1659 
29 
 
Phibbs and 
Schmitt [47] 
1998-2000 USA 
(California) 
Retrospective 
analysis of 
state-level 
linked vital 
statistics and 
discharge 
records 
34-36 weeks: 
84,540 
≥37 weeks: 
92,421 
 
34-36  
≥37 
Hospital US$, 2003 Initial 
hospital-
ization 
34-36 weeks: 5,424 
≥37 weeks: 2,027 
Ringborg et al 
[48] 
1998-2001 Sweden Retrospective 
analysis of 
hospital 
discharge 
records 
34-36 weeks: 
4727 
≥37 weeks: 
16,852 
 
34-36  
≥37 
Hospital €, 2001 First year of 
life 
Inpatient cost per survivor: 
34-36 weeks: 14,177 
≥37 weeks: 6,801 
St John et al 
[49] 
1989-1992 USA 
(Alabama) 
Retrospective 
analysis of 
hospital charts 
and billing 
database 
34-36 weeks: 
103 
≥37 weeks: 197 
 
34-36  
≥37 
Hospital US$, price 
date not 
specified 
Initial 
hospital-
ization 
34-36 weeks: 10,961 
≥37 weeks: 6,953 
van Baaren et 
al [50]  
2006-2012 Netherlands Retrospective 
analysis of one 
prospective 
cohort study 
and three 
randomised 
controlled 
trials 
4,552  
1090 singletons 
3462 multiples 
24–28  
28–32  
32–36 
≥37 
Hospital €, 2011  Initial 
hospital-
ization 
34 weeks: 
Singletons: 11,222; multiples: 
21,457 
35 weeks: 
Singletons: 6492; multiples: 
14,306 
36 weeks: 
Singletons: 2924; multiples: 
8618 
≥37 weeks: 
Singletons: 1434; multiples: 
5201 
Xu et al [51]  2003 USA 
(Michigan) 
Retrospective 
analysis of 
regional birth 
cohort 
<37 weeks: 9780  
≥37 weeks: 
101,484  
≥20  Hospital US$, 2007  Initial 
hospital-
ization 
34 weeks: 18,617 
35 weeks: 15,864 
36 weeks: 12,305 
≥37 weeks: 6368 
± Cost per live birth unless otherwise stated. 
